Google
DBVT — DBV TECHNOLOGIES (Healthcare >> Biotechnology)
DBVT FAQ
What is DBVT's ROE?
DBV TECHNOLOGIES reports a Return on Equity (ROE) of -80.74%.
What is DBVT's dividend yield?
DBV TECHNOLOGIES offers a dividend yield of 0.00%.
What is DBVT's Deepscope Quality Score?
Deepscope rates DBVT's overall financial quality at 46 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy DBVT?
Deepscope's AI Timing Score for DBVT is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does DBVT belong to?
DBV TECHNOLOGIES is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 17.58
Price
-0.12
(-0.68%)
Day Change
|
|
|---|
DBVT, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
平均ROEが低い
ROAがROEに比べて低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not quite good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 86 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 17.58 |
| PBV / Sector |
5.04 / 4.58
|
| Earning Per Share | -2.82 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
4.07 M
GREAT
|
| Average 1W Daily Value |
3.81 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
43% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-05 09:12:28 |
| Symbol | DBVT |
| Name | DBV TECHNOLOGIES |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 59.19 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,047.60 / 8,655.90 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: BAtiment IRO, Châtillon, France, 92320
Phone: 33 1 55 42 78 78
Website: https://www.dbv-technologies.com
Employees: 161
Sector: Healthcare >> Biotechnology
Description: DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs include celiac disease. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
